Atossa Therapeutics (ATOS) Profit After Tax (2011 - 2026)

Atossa Therapeutics (ATOS) has reported Profit After Tax for 16 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 42.74% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 43.0% YoY), while the FY2025 annual figure was -$34.8 million, down 36.45% from the prior year.
• Profit After Tax climbed to -$9.6 million in Q1 2026 per ATOS's latest filing, from -$11.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$4.8 million in Q1 2022 and bottomed at -$11.0 million in Q4 2025.
• Historically, Profit After Tax has averaged -$7.5 million across 5 years, with a median of -$7.2 million in 2024.
• Annual changes were most pronounced in 2024 — Profit After Tax surged 38.46% — and 2025, when it plunged 72.79%.
• Atossa Therapeutics' Profit After Tax stood at -$7.4 million in 2022, then fell by 4.26% to -$7.8 million in 2023, then rose by 18.15% to -$6.3 million in 2024, then slumped by 72.79% to -$11.0 million in 2025, then increased by 12.56% to -$9.6 million in 2026.
• Business Quant data shows ATOS's Profit After Tax at -$9.6 million in Q1 2026, -$11.0 million in Q4 2025, and -$8.7 million in Q3 2025.